Randomised EValuation of Therapies for microvAscuLar Injury in STEACS
A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 250 participants.
Also called NCT06935383
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose other
- Phase
- Phase 2
- Enrolled
- 250 participants
- Sponsor
- CorFlow Therapeutics AG
- Registry
-
NCT06935383
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT06935383. Randomized; single masking; primary purpose other. Start 2025-09 (anticipated); primary completion 2027-09 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Randomised EValuation of Therapies for microvAscuLar Injury in STEACS
- Acronym
- REVITALISE
- Condition
- STEMI (ST Elevation MI)
- Intervention (Device)
- Therapeutic sequence
- Intervention (Device)
- Diagnostic sequence
- Lead sponsor
- CorFlow Therapeutics AG
Record details
- Record id
cardio:ct-nct06935383- Content hash
f345af8841ad6e867ebaba8b607f1de73a4653717c4be834ee866fe7c50d2d61